A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer Meeting Abstract
| Authors: | Vaishampayan, U. N.; Narayan, V.; Wise, D.; Lang, J. M.; Lowentritt, B. H.; Mellado, B.; Carles, J.; Saez, M. I.; Abida, W.; Taplin, M. E.; Azad, A.; Wang, K.; Barbash, O.; Ferron-Brady, G.; Fecteau, D.; Khaled, A. H.; Dhar, A.; De Bono, J. S. |
| Abstract Title: | A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer |
| Meeting Title: | 2018 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2018 Feb 8-10 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-02-20 |
| Language: | English |
| ACCESSION: | WOS:000436179500385 |
| DOI: | 10.1200/JCO.2018.36.6_suppl.TPS391 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS391 -- Source: Wos |
